Skip Navigation

COVID-19 Update

Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.

Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts

David S Ettinger, M.D.

Headshot of David S Ettinger
  • Alex Grass Professor in Oncology
  • Professor of Oncology
Male

Expertise

Connective Tissue Diseases, Lung Cancer, Medical Oncology, Sarcoma ...read more

Research Interests

oncology; lung cancer; non-small cell lung cancer

Request an Appointment

Insurance Information

Maryland Phone

410-955-8964

Outside of Maryland

410-464-6641
Request Appointment

International Patients

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-955-8964

Background

David Ettinger, M.D., received his medical degree from the University of Louisville School of Medicine and has been in practice for more than 20 years.  

...read more

Titles

  • Alex Grass Professor in Oncology
  • Professor of Oncology
  • Professor of Gynecology and Obstetrics
  • Professor of Medicine
  • Professor of Otolaryngology - Head and Neck Surgery
  • Professor of Radiation Oncology and Molecular Radiation Sciences

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD; University of Louisville School of Medicine (1967)

Fellowships

  • Oncology; Johns Hopkins University School of Medicine (1975)
  • Internal Medicine; Mayo Clinic (1971)

Board Certifications

  • American Board of Internal Medicine (Internal Medicine) (1976)
  • American Board of Internal Medicine (Medical Oncology) (1977)

Research & Publications

Selected Publications

View all on PubMed

Ettinger, D.S. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist. 2006 Apr;11(4):358-373.

Ettinger, D.S.; Aisner, J. Changing face of small-cell lung cancer: real and artifact. J Clin Oncol. 2006 Oct 1;24(28):4526-4527.

Ettinger, D.S.; Bepler, G.; Bueno, R.; Chang, A.; Chang, J.Y.; Chirieac, L.R.; D''Amico, T.A.; Demmy, T.L.; Feigenberg, S.J.; Grannis, F.W., Jr.; Jahan, T.; Jahanzeb, M.; Kessinger, A.; Komaki, R.; Kris, M.G.; Langer, C.J.; Le, Q.T.; Martins, R.; Otterson, G.A.; Robert, F.; Sugarbaker, D.J.; Wood, D.E. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jul;4(6):548-582.

Johnson, B.E.; Crawford, J.; Downey, R.J.; Ettinger, D.S.; Fossella, F.; Grecula, J.C.; Jahan, T.; Kalemkerian, G.P.; Kessinger, A.; Koczywas, M.; Langer, C.J.; Martins, R.; Marymont, M.H.; Niell, H.B.; Ramnath, N.; Robert, F.; Williams, C.C., Jr. Small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Jul;4(6):602-622.

Kraybill, W.G.; Harris, J.; Spiro, I.J.; Ettinger, D.S.; DeLaney, T.F.; Blum, R.H.; Lucas, D.R.; Harmon, D.C.; Letson, G.D.; Eisenberg, B. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006 Feb 1;24(4):619-625.

Blakeley, J.; Laterra, J. Neurotoxicities. In: Ettinger, D.S.; Donehower, R., editors, Current Cancer in Therapeutics: Springer; 2007.
Brahmer, J.R.; Ettinger, D.S. Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapy. Respirology. 2007 May;12(3):320-325.

Dunbar, E.; Laterra, J. Malignant glioma. In: Ettinger, D.S.; Donehower, R., editors: Current Cancer Therapeutics; 2007. p. In press.
Juergens, R.; Brahmer, J.; Ettinger, D. Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. Cancer Chemother Pharmacol. 2007 Apr;59(5):621-629.

Brahmer, J.R. Lung Cancer. In: Donehower, R.; Ettinger, D., editors. 5th Edition ed, Current Cancer Therapeutics. New York, NY: Churchill-Livingstone; 2008.

Brandes, J.C.; Yung, R.C. Pulmonary and Cardiovascular Complications of Cancer Therapy. In: Ettinger, D.; Donehower, R., editors, Current Cancer Therapeutics, Fifth Edition: Current Medicine, LLC; 2008.

Dhall, G.; Finlay, J.L.; Dunkel, I.J.; Ettinger, L.J.; Kellie, S.J.; Allen, J.C.; Egeler, R.M.; Arceci, R.J. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer. 2008 Jan;50(1):72-79.

el-Shami, K.; Forastiere, A.A. Head and Neck Cancer. In: Ettinger, D., et al, editor. 5th Edition ed, Current Cancer Therapeutics. New York, NY: Churchill-Livingstone; 2008.

Ettinger, D.S.; Akerley, W.; Bepler, G.; Chang, A.; Cheney, R.T.; Chirieac, L.R.; D''Amico, T.A.; Demmy, T.L.; Feigenberg, S.J.; Figlin, R.A.; Govindan, R.; Grannis, F.W., Jr.; Jahan, T.; Jahanzeb, M.; Kessinger, A.; Komaki, R.; Kris, M.G.; Langer, C.J.; Le, Q.T.; Martins, R.; Otterson, G.A.; Patel, J.D.; Robert, F.; Sugarbaker, D.J.; Wood, D.E. Non-small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar;6(3):228-269.

Ettinger, D.S.; Grunberg, S.M.; Hauber, A.B.; Mohamed, A.F. Evaluation of the relative importance of chemotherapeutic and antiemetic efficacy in various oncologic settings. Support Care Cancer. 2008 Sep 2.
Le, D.; Kim, P.; Jaffee, E.M. Current Cancer Therapeutics. In: David Ettinger, R.D., editor, Cancer Vaccines. Philadelphia: Current Medicine, LLC; 2008.

Messersmith, W.A.; Jimeno, A.; Ettinger, D.; Laheru, D.; Brahmer, J.; Lansey, D.; Khan, Y.; Donehower, R.C.; Elsayed, Y.; Zannikos, P.; Hidalgo, M. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008 Dec;63(1):181-188.

Pili, R., J. Walczak, M. A. Carducci, and S. R. Denmeade. Genitourinary Cancer. In: Donhower, D.E.a.R., editor, Current Cancer in Therapeutics. Philadelphia: Current Medicine Group; 2008.

Choy, H.; Jain, A.K.; Moughan, J.; Curran, W.; Whipple, G.; Demas, W.F.; Ettinger, D.S. RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer. J Thorac Oncol. 2009 Jan;4(1):80-86.

Guarino, M.J.; Schneider, C.J.; Hosford, M.D.; Brahmer, J.R.; Rudin, C.M.; Finkenstein, F.G.; Philip-Norton, R.E.; Lue, H.; Weber, M.R.; Ettinger, D.S. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies. Oncologist. 2009;14(2):119-124.

Sandford, G.R.; Schumacher, U.; Ettinger, J.; Brune, W.; Hayward, G.S.; Burns, W.H.; Voigt, S. Deletion of the rat cytomegalovirus immediate early 1 gene results in a virus capable of establishing latency but with lower levels of acute virus replication and latency that compromise reactivation efficiency. J Gen Virol. 2009 Nov 18.

Aisner, S.C.; Dahlberg, S.; Hameed, M.R.; Ettinger, D.S.; Schiller, J.H.; Johnson, D.H.; Aisner, J.; Loehrer, P.J. Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. J Thorac Oncol. 2010 Jun;5(6):885-892.

Balmanoukian, A.; Ettinger, D.S. Managing the patient with borderline resectable lung cancer. Oncology (Williston Park). 2010 Mar;24(3):234-241.

Ettinger, D.S. Emerging profile of cetuximab in non-small cell lung cancer. Lung Cancer. 2010 Jun;68(3):332-337.

Ettinger, D.S.; Akerley, W.; Bepler, G.; Blum, M.G.; Chang, A.; Cheney, R.T.; Chirieac, L.R.; D''Amico, T.A.; Demmy, T.L.; Ganti, A.K.; Govindan, R.; Grannis, F.W., Jr.; Jahan, T.; Jahanzeb, M.; Johnson, D.H.; Kessinger, A.; Komaki, R.; Kong, F.M.; Kris, M.G.; Krug, L.M.; Le, Q.T.; Lennes, I.T.; Martins, R.; O''Malley, J.; Osarogiagbon, R.U.; Otterson, G.A.; Patel, J.D.; Pisters, K.M.; Reckamp, K.; Riely, G.J.; Rohren, E.; Simon, G.R.; Swanson, S.J.; Wood, D.E.; Yang, S.C. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010 Jul;8(7):740-801.
Ettinger, D.S.; Akerley, W.; Bepler, G.; Blum, M.G.; Chang, A.; Cheney, R.T.; Chirieac, L.R.; D''Amico, T.A.; Demmy, T.L.; Govindan, R.; Grannis, F.W., Jr.; Jahan, T.; Johnson, D.H.; Kessinger, A.; Komaki, R.; Kong, F.M.; Kris, M.G.; Krug, L.M.; Le, Q.T.; Lennes, I.T.; Martins, R.; O''Malley, J.; Osarogiagbon, R.U.; Otterson, G.A.; Patel, J.D.; Pisters, K.M.; Reckamp, K.; Riely, G.J.; Rohren, E.; Swanson, S.J.; Wood, D.E.; Yang, S.C. Thymic malignancies. J Natl Compr Canc Netw. 2010 Nov;8(11):1302-1315.

Ettinger, D.S.; Jotte, R.; Lorigan, P.; Gupta, V.; Garbo, L.; Alemany, C.; Conkling, P.; Spigel, D.R.; Dudek, A.Z.; Shah, C.; Salgia, R.; McNally, R.; Renschler, M.F.; Oliver, J.W. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol. 2010 May 20;28(15):2598-2603.

Hann, C.L. Managing Risk-What if My Cancer Comes Back?: Jones and Bartlett; 2010.

Kraybill, W.G.; Harris, J.; Spiro, I.J.; Ettinger, D.S.; DeLaney, T.F.; Blum, R.H.; Lucas, D.R.; Harmon, D.C.; Letson, G.D.; Eisenberg, B. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer. 2010 Oct 1;116(19):4613-4621.

Videos & Media

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 

Comments

Loading...
Is this you? Edit Profile
back to top button